MedTrace Logo

Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

NCT04352855 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2020-04-20

No results posted yet for this study

Summary

The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.

Conditions

  • Ventilator Associated Pneumonia
  • Antibiotic Resistant Infection

Interventions

DRUG

Ceftolozane/tazobactam

Administration

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2020-05-19
Completion
2020-05-19

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352855 on ClinicalTrials.gov